Pregled bibliografske jedinice broj: 431815
CSF total tau and phosphorylated tau proteins in the differential diagnosis of dementia
CSF total tau and phosphorylated tau proteins in the differential diagnosis of dementia // Abstracts of the 13th Congress of the European Federation of Neurological Societies ; u: European Journal of Neurology 16 (2009) (S3) / Lenzi, G.L. ; Federico, A. (ur.).
Beč: EFSN, 2009. str. 343-343 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 431815 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
CSF total tau and phosphorylated tau proteins in the differential diagnosis of dementia
Autori
Boban, Marina ; Šarac, Helena ; Mladinov, Mihovil ; Süßmair, Christine ; Ackl, Nibal ; Bader, Benedikt ; Danek, Adrian ; Hof, Patrick ; Šimić, Goran
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 13th Congress of the European Federation of Neurological Societies ; u: European Journal of Neurology 16 (2009) (S3)
/ Lenzi, G.L. ; Federico, A. - Beč : EFSN, 2009, 343-343
Skup
Congress of the European Federation of Neurological Societies (13 ; 2009)
Mjesto i datum
Firenca, Italija, 12.09.2009. - 15.09.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
aging; Alzheimer's disease; cerebrospinal fluid; dementia; early diagnosis; ELISA; neurofibrillary degeneration; tau protein
Sažetak
Alzheimer’ s disease (AD) and frontotemporal dementia (FTD) represent an important differential diagnostic problem in clinical practice. The identification for new biomarkers that would help establishing the diagnosis and primary cause of the dementia is therefore of great relevance. The aim of this study was to investigate the diagnostic accuracy of three potential CSF biomarkers, total tau protein (t-tau), tau protein phosphorylated at threonine 181 (p-tau181) and tau protein phosphorylated at serine 199 (p-tau199), in the differential diagnosis of AD and FTD patients in relatively young age groups. The concentrations of these three CSF biomarkers were measured in 25 FTD patients, 27 AD patients and 25 control subjects. The CSF concentrations of all three markers were significantly higher in AD than in FTD patients (p<0.001) or control subjects (p<0.001). No difference was observed in FTD patient group compared to controls, except for p-tau181 (p=0.028).When sensitivity was set at 85% or higher, specificity in differentiation between FTD and AD patients reached 40% for t-tau, 37.5% for p-tau181 and 56% for p-tau199. Improvement of the diagnostic accuracy upon logistic regression analysis with t-tau and p-tau199 as independent variables showed that 22 out of 25 FTD patients could be correctly classified. In conclusion, none of the markers per se fulfilled the criteria for the “ ideal” marker (sensitivity and specificity higher than 85%). However, combination of t-tau and p-tau199 detected correctly 88% of FTD patients, thus largely satisfying practical requirements.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija
POVEZANOST RADA
Projekti:
108-1081870-1942 - Fosforilacija tau proteina u razvitku i Alzheimerovoj bolesti (Šimić, Goran, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE